Skip to main content

Table 5 mRNA vaccine cancer therapeutics in clinal trials

From: Research progress on non-protein-targeted drugs for cancer therapy

Intervention

Cancer

ClinicalTrials. gov Identifier

Current status

DC vaccine

Breast cancer, malignant melanoma

NCT00978913

Phase I completed

DC vaccine

AML

NCT01734304

Phase I/II completed

DC vaccine

Melanoma

NCT00940004

Phase I/II completed

DC vaccine with mRNA from tumor stem cells

GBM

NCT00846456

Phase I/II completed

mDC vaccine/ pDC vaccine

mCRPC

NCT02692976

Phase II completed

DC vaccine plus cisplatin

Melanoma

NCT02285413

Phase II completed

DC vaccine plus docetaxel

mCRPC

NCT01446731

Phase II completed

DC vaccine

AML

NCT05000801

Recruiting

DC vaccine plus temozolomide

GBM

NCT02649582

Phase I/II recruiting

DC vaccine plus temozolomide

High grade glioma, diffuse intrinsic pontine glioma

NCT04911621

Phase I/II recruiting

DC vaccine

AML

NCT01686334

Phase II recruiting

DC vaccine plus radiotherapy and IFN-α

Malignant melanoma

NCT01973322

Phase II recruiting

RNA-loaded DC vaccine plus basiliximab

Malignant neoplasms brain

NCT00626483

Phase I completed

TriMix-DC

Melanoma

NCT01066390

Phase I completed

TriMix-DC plus ipilimumab

Melanoma

NCT01302496

Phase II completed

TriMix

Breast cancer

NCT03788083

Phase I recruiting

BTSC mRNA-loaded DCs

GBM

NCT00890032

Phase I completed

CT7, MAGE-A3, and WT1 mRNA-electroporated LCs

Multiple myeloma

NCT01995708

Phase I completed

CEA-loaded DC vaccine

CRC

NCT00228189

Phase I/II completed

MiHA-loaded PD-L-silenced DC

Hematological malignancies

NCT02528682

Phase I/II completed

mRNA transfected DC

Androgen resistant metastatic prostate cancer

NCT01278914

Phase I/II completed

GRNVAC1

AML

NCT00510133

Phase II completed

mRNA transfected DC plus docetaxel

Prostate cancer

NCT01446731

Phase II completed

Human CMV pp65-LAMP mRNA-pulsed autologous DCs

GBM

NCT02366728

Phase II completed

Human CMV pp65-LAMP mRNA-pulsed autologous DCs with or without varlilumab

GBM

NCT03688178

Phase II recruiting

pp65-shLAMP DC with GM-CSF/ pp65-flLAMP DC with GM-CSF

GBM

NCT02465268

Phase II recruiting

Autologous DCs loaded with autologous tumor RNA

Uveal melanoma

NCT01983748

Phase III recruiting

CV9103

HRPC

NCT00831467

Phase I/II completed

CV9103

HRPC

NCT00906243

Phase I/II Terminated (Study closed after completion of Phase I)

CV9104

Prostate Cancer

NCT01817738

Phase I/II terminated (Follow up period after primary analysis was prematurely stopped because more mature data will not impact the study outcome)

CV9104

Prostate Cancer

NCT02140138

Phase II terminated (Recruitment was terminated after enrolment of 35 instead of 36 evaluable patients for administrative reasons.)

CV9201

NSCLC

NCT00923312

Phase I/II completed

CV9202 and local radiation

NSCLC

NCT01915524

Phase I terminated (Slow recruitment in stratum 3: enrolled only 2 instead of 8 pts. within predicted time)

CV9202 plus durvalumab and tremelimumab

NSCLC

NCT03164772

Phase I/II completed

mRNA-5671/V941 with or without pembrolizumab

KRAS mutant advanced or metastatic NSCLC, CRC or pancreatic adenocarcinoma

NCT03948763

Phase I completed

mRNA-2416 plus durvalumab

Advanced malignancies

NCT03323398

Phase I/II terminated (This study was halted prematurely because the efficacy endpoints were not met for either treatment arm.)

mRNA-4157 plus Pembrolizumab

Melanoma

NCT03897881

Phase II active, not recruiting

mRNA-4157 plus pembrolizumab

Solid tumors

NCT03313778

Phase I recruiting

mRNA-2752 plus durvalumab

Advanced or metastatic solid tumor malignancies or lymphoma

NCT03739931

Phase I recruiting

mRNA-4359 plus pembrolizumab

Advanced solid tumors

NCT05533697

Phase I/II recruiting

mRNA RNA loaded lipid particles

GBM

NCT04573140

Phase I recruiting

OTX-2002

HCC and other solid tumor types known for association with the MYC oncogene

NCT05497453

Phase I/II recruiting

BNT141 plus nab-paclitaxel and gemcitabine

Advanced unresectable or metastatic CLDN18.2-positive solid tumors

NCT04683939

Phase I/II recruiting

BNT113

HPV16 + head and neck cancer

NCT03418480

Phase I/II recruiting

BNT113 plus pembrolizumab

Unresectable head and neck SCC

NCT04534205

Phase II recruiting

BNT111

Melanoma

NCT02410733

Phase I active, not recruiting

BNT111 plus cemiplimab

Unresectable Stage III or IV melanoma

NCT04526899

Phase II recruiting

Stabilized tumor-mRNA plus GM-CSF

Malignant melanoma

NCT00204607

Phase I/II completed

mRNA coding for melanoma associated antigens plus GM-CSF

Malignant melanoma

NCT00204516

Phase I/II completed

Personalized cellular vaccine

Brain cancer

NCT02808416

Phase I completed

Neoantigen tumor vaccine with or without PD-1/L1

Advanced gastric cancer, esophageal cancer, and liver cancer

NCT05192460

Recruiting

Neoantigen mRNA personalised cancer SW1115C3

Advanced malignant solid tumors

NCT05198752

Phase I recruiting

RO7198457 with or without atezolizumab

Advanced or metastatic tumors

NCT03289962

Phase I active, not recruiting

RO7198457 plus atezolizumab and mFOLFIRINOX

Pancreatic cancer

NCT04161755

Phase I active, not recruiting

RO7198457 plus pembrolizumab

Advanced melanoma

NCT03815058

Phase II active, not recruiting

RO7198457

Stage II and stage III colorectal cancer

NCT04486378

Phase II recruiting

HB-201

HPV 16 + confirmed oropharynx cancer, cervical cancer

NCT04630353

Early Phase 1 recruiting

GRANITE (GRT-C901/GRT-R902)

Colon cancer

NCT05456165

Phase II recruiting

  1. DC dendritic cell, mDC myeloid dendritic cells, pDC plasmacytoid dendritic cells, LCs langerhans cells, GM-CSF granulocyte–macrophage colony-stimulating factor, CEA carcinoembryonic antigen, mCRPC metastatic castration-resistant prostate cancer, AML acute myeloid leukemia, GBM glioblastoma, mCRPC metastatic castration-resistant prostate cancer, CRC Colorectal cancer, AML acute myelogenous leukemia, HRPC hormonal refractory prostate cancer, NSCLC non-small cell lung cancer, HCC hepatocellular carcinoma, CLDN18.2 Claudin 18.2, SCC squamous cell carcinoma